Background/objectives Thyroid-associated ophthalmopathy (TAO), an autoimmune component of Graves' disease, remains a disfiguring and potentially blinding condition. Here, the author reviews the role of insulin-like growth factor-I receptor pathway in TAO and how it might be therapeutically targeted. Methods The recent literature is reviewed.
Introduction to the insulin-like growth factor-I receptor
The insulin-like growth factor-I (IGF-I) pathway plays critical roles in the regulation of cell metabolism, survival, and growth [1, 2] . The pathway comprises both IGF-I and IGF-II, two surface receptors, including IGF-I receptor (IGF-IR) and IGF-IIR/mannose-6-phosphate receptor, six IGF-I binding proteins and nine IGF-I binding protein-related proteins [2] [3] [4] . Its involvement in immune function has been recognized for several decades and is now being considered as a target for therapy in human autoimmune diseases [5] . IGF-IR is a membrane-spanning tyrosine kinase protein that can bind IGF-I and IGF-II [6] . It can also be activated by insulin although IGF-I is its preferred agonist ligand. It exhibits a heterotetrameric structure that includes an extracellular ligand binding domain located in two α subunits and a kinase domain located in two β subunits. These subunits are linked by two disulphide bonds. Further, IGF-IR and the insulin receptor can form heterodimers and many tissues, such as fat, may be dominated by hybrid receptors [7, 8] . Human IGF-IR is encoded by a gene located on chromosome 15. The receptor is ubiquitously expressed in many tissues and cell types. Its activities are regulated by several proteins, among them the IGF-I binding proteins which govern the interactions between IGF-IR and activating ligands [3] . Substantial evidence supports the concept that IGF-IR participates in the pathogenesis of several forms of cancer [9] . This realization resulted in the initiation of several drug development programs at multiple pharmaceutical companies [10] . Most of these programs have been terminated because these drugs failed to exhibit encouraging effectiveness against several forms of cancer. Recent insights into the signaling downstream from IGF-IR have added several layers of complexity to how we now view the central importance of this pathway in human physiology and disease [11] .
Evidence for IGF-IR involvement in Graves' disease
Graves' disease (GD) represents an autoimmune syndrome involving the thyroid, orbital connective tissues, and specific regions of the skin [12] . The central autoantigen in GD is the thyrotropin receptor (TSHR). Activating antibodies directed against TSHR, known as thyroid-stimulating immunoglobulins (TSI), are directly responsible for the hyperthyroidism frequently occurring in GD [13] . The role of TSHR and TSI in the development of thyroid-associated ophthalmopathy (TAO) remains less well defined although substantial evidence, much of it circumstantial, supports their involvement. Emerging insights suggest that a second cell surface receptor might also play an important role in GD and in TAO [14] . A major obstacle to better defining the underlying pathogenesis of TAO has been the historical absence of a high-fidelity animal model for the disease although recent progress in developing these models now offers a promising platform for preclinical investigation [15] . The first clue that IGF-IR might be involved in TAO was provided by Weightman and colleagues [16] . They had speculated that earlier observations concerning immunoglobulins from patients with GD (GD-IgG) stimulating fibroblasts and extraocular myoblasts [17, 18] might be acting through IGF-IR. They reported that IgG collected from patients with GD, regardless of whether or not they manifested TAO, could displace radiolabeled IGF-I from binding sites on the surfaces of orbital fibroblasts generated from tissues explanted from extraocular muscle. Those binding sites had an apparent Kd of 0.5 nM. In contrast, IgG from healthy controls failed to alter IGF-I binding to these cells. Independently, Ingbar and colleagues laid the groundwork for many of the studies that have followed dissecting the relationship between the thyroid axis and growth hormone/IGF-I pathways. They had previously found that IGF-I and insulin could synergistically enhance the actions of TSH and TSI on thyroid epithelial cells in culture [19] .
More recently, Pritchard et al. [20] demonstrated that IGF-IR is overexpressed by orbital fibroblasts from patients with TAO. Interrupting IGF-IR activity, either with inhibitory anti-IGF-IR antibodies or by transfecting orbital fibroblasts with a dominant negative receptor, could abolish signaling initiated by GD-IgG [20] . The signaling mediating the actions of GD-IgG in these cells has been mapped to the FRAP/mTor/p70 sk6 pathway and is rapamycin-sensitive [21] . Subsequently, T cells were also found to overexpress IGF-IR [22] and the relative abundance of IGF-IR-displaying B cells in GD [23] was found to be increased. Thus, several clues existed that IGF-IR might be involved in GD and TAO, providing the rationale for considering this pathway as a potential therapeutic target.
Evidence that antibodies against IGF-IR might be generated in GD
The studies from Weightman et al [16] suggested that GDIgG might include molecules exhibiting affinity toward a fibroblast surface-displayed protein that also binds IGF-I. While those studies identified IGF-IR as a strong candidate for this binding, Pritchard et al. [20] ultimately established the identity of the binding site as IGF-IR. Using the specific IGF-I analogue, Des 1-3, they showed that the principal IGF-I binding site on orbital fibroblasts is IGF-IR and that GD-IgG could compete for this site. Their studies further demonstrated that GD-IgG could mimic the actions of IGF-I while rhTSH failed to do so [20] . Among its effects, GDIgG was shown to induce the expression of the chemokine known as "regulated on activation normal T cell expressed and secreted" (RANTES) and IL-16 [20, 21] . These two T cell chemoattractants play important roles in the trafficking of cells to sites of tissue damage and remodeling [24, 25] . The existence of antibodies directed at IGF-IR, and especially those with IGF-IR-activating properties, as distinct from anti-TSHR antibodies, has been contentious. Some studies have failed to detect these [26, 27] while others have demonstrated anti-IGF-IR antibodies [16, 28, 29] . Further, anti-IGF-IR antibodies have been detected in a mouse model of GD manifesting some features of TAO [30] . At the heart of the debate is whether all activities of GD-IgG can correctly be attributed to those antibodies activating TSHR. Speaking against that possibility are the findings of Pritchard et al. [31] demonstrating identical IGF-IR signalinitiating activities in sera and IgGs from patients with rheumatoid arthritis but not manifesting GD. Underlying the divergent findings thus far reported may be the substantially different assays used to detect anti-IGF-IR antibodies and lack of standardization of the cell models used in each case. In any event, the issue of whether anti-IGF-IR antibodies, generated as a consequence of disease, can in some manner directly initiate signaling through that receptor is yet to be settled (Fig. 1) .
Evidence that IGF-IR and TSHR might interact
The initial evidence for an overlap between TSH and IGF-I (and insulin) pathways dates from the studies of Ingbar and colleagues 30 years ago [19] . They reported that both IGF-I and insulin could enhance the actions of TSH and TSIs in cultured FRTL5 cells. The relationship between IGF-IR and TSHR was demonstrated initially by Tsui et al. [32] who found that the two membrane-spanning proteins co-localize under confocal microscopy of orbital fibroblasts, cultured human thyroid epithelial cells, and in situ in orbital fat derived from patients with TAO. Their studies included coimmunoprecipitation studies which revealed that the two receptor proteins could be brought out of the solution with monoclonal antibodies against either receptor. With regard to co-dependent function, the study further demonstrated that an inhibitory monoclonal antibody directed against IGF-IR (1H7) could block signaling initiated at either IGF-IR or TSHR. Specifically, the activation of Erk by IGF-I, rhTSH, or IgGs from patients with GD could be attenuated by 1H7 [32] . In aggregate, that study strongly suggested the potential for interruption of IGF-IR activity as a therapy for diseases mediated by IGF-I, TSI, and activating antibodies directed against both receptors.
Organization of clinical trials based on findings in vitro
A multicenter randomized, placebo-controlled, doublemasked clinical trial was conducted to determine whether inhibiting IGF-IR with a fully human, monoclonal antibody was effective and safe in moderate to severe, active TAO [33] (Fig. 2) . Study enrollment was limited to patients who were 18-75 years old, who had manifested TAO within 9 months of study entry, who had clinical activity scores (CAS) of ≥4 points on a 7-point scale and whose eye disease was judged to be moderate to severe in the more severely affected (study) eye. The study design included baseline assessment, entry into a 24-week treatment period during which patients received 8 infusions at 3 weekly intervals followed by a 48-week follow-up. The primary response, assessed at week 24 (3 weeks after the final infusion), comprised the aggregate of a reduction of ≥2 points in CAS and a reduction of ≥2 mm in proptosis in the study eye without a similar magnitude of worsening in the fellow eye. Secondary endpoints included reduction in proptosis, improvement in CAS, improvement in the quality of life using a validated instrument, and improved diplopia as independent variables. A total of 112 patients underwent screening of which 88 were randomized to either the treatment arm receiving teprotumumab or placebo in a 1:1 ratio. Thirty-nine patients receiving placebo (87%) and 37 patients in the teprotumumab group (88%) completed the intervention.
Twenty-nine patients of forty-two (69%) receiving teprotumumab in the intention to treat cohort responded at Fig. 2 Screening, randomization, response and follow-up of patients' participation in a clinical trial of teprotumumab. a Patients entered the trial screening process after they had met the inclusion criteria. They were randomized in a 1:1 ratio to receive teprotumumab or placebo during the 24-week treatment phase and were followed for 1-year of observation. b contains analysis to first response. 24 weeks as compared to 9 of 45 patients in the placebo group (20%) (p < 0.001). Patients receiving the drug had a greater reduction in proptosis (p < 0.001), CAS (p < 0.001), and improved quality of life at 24 weeks compared to placebo. Time to first response was substantially shorter in the teprotumumab group than in those receiving placebo. Eighteen of forty-two patients (43%) receiving active drug achieved the primary endpoint at 6 weeks, indicating a very rapid response to teprotumumab. In contrast, 2 of 45 patients (4%) receiving placebo responded at 6 weeks (p < 0.001). With regard to safety, hyperglycemia detected in patients with preexisting diabetes was the only drug-related adverse event and was easily controlled with adjustment of diabetes medication. This increased requirement in medication was transient and returned to baseline following the conclusion of exposure to teprotumumab.
Thus, in patients with active, moderate to severe TAO, inhibition of IGF-IR with teprotumumab was more effective than placebo in improving CAS and proptosis while exhibiting an encouraging safety profile. On the basis of the results of this phase II trial, the US FDA designated teprotumumab as a breakthrough therapy for TAO. Longterm follow-up results are now being analyzed. In addition, a second, confirmatory trial was organized and has now completed enrollment. That trial, like the first, is limited to patients with relatively recent onset of TAO (≤9 months) but has a simplified primary endpoint consisting of reduction in proptosis of ≥2 mm in the study eye with no similar magnitude worsening in the fellow eye. In addition, all nonresponders, regardless of whether they were in the teprotumumab cohort or those who had received placebo during the treatment phase, are offered a 24-week treatment of the active drug as an open label study phase.
The reported trial has limitations. Despite attempts to stratify participants with tobacco smoking histories, an imbalance existed. The study did not include orbital imaging that would allow pre-and post-treatment comparisons. This could have helped determine whether teprotumumab targeted extraocular muscles, adipose/connective tissue, or both. The duration of follow-up observation has thus far been inadequate to fully reveal the durability and long-term safety of the drug. We anticipate that these gaps in our current understanding will be filled with subsequent investigations.
Implications of the findings from clinical trials of teprotumumab in TAO
The positive results thus far reported for teprotumumab are unprecedented with regard to effectiveness. They appear to be equivalent to the best results thus far reported for surgical orbital decompressions in TAO. Thus they are likely to alter the patterns of medical care for this vexing and disfiguring condition should the currently conducted trial reveal similar effectiveness and safety. It is possible that other autoimmune diseases might similarly benefit from inhibition of the IGF-IR [5] . For instance, an identical mechanism for the involvement of that receptor was reported by our group in rheumatoid arthritis more than 1 decade ago [31] and thus that disease might represent an ideal candidate for further clinical study.
Conclusions
Initial results from a multicenter clinical trial suggest that the inhibition of IGF-IR with a specific monoclonal antibody, teprotumumab, might result in substantial improvement of TAO with a favorable safety profile. This therapeutic approach was predicated entirely on observations made at the laboratory bench and thus provided physiological plausibility for the remarkable trial outcomes. A follow-up trial is now being conducted to confirm the encouraging results of the first study. Should those results prove similar to the initial study, it is possible that teprotumumab might replace surgical rehabilitation of the orbital tissues, potentially reducing morbidity and improving the outcomes associated with the disease. Questions concerning whether teprotumumab will be effective in stable TAO must await further investigation.
